Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2004
10/21/2004WO2004073592A3 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier
10/21/2004WO2004073375A8 Podophyllotoxin derivatives as antitumor agents
10/21/2004WO2004071481B1 Melanogenesis inhibitor and skin preparation containing the same
10/21/2004WO2004071402A3 STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
10/21/2004WO2004069832A3 Antibacterial agents
10/21/2004WO2004067482A3 Substituted anilide ligands for the thyroid receptor
10/21/2004WO2004066960A3 Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
10/21/2004WO2004065380A8 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
10/21/2004WO2004060318A3 Drug-coated stents and methods of use therefor
10/21/2004WO2004058144A3 Antibacterial agents
10/21/2004WO2004056843A3 10-substituted macrolide antibiotics
10/21/2004WO2004054968A3 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
10/21/2004WO2004052348A3 Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
10/21/2004WO2004050012A3 Ifosfamide compositions for parenteral administration and a process for their preparation
10/21/2004WO2004047765A3 Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass
10/21/2004WO2004047760A3 Novel chemical compounds
10/21/2004WO2004047749A3 Purinergic modulation of smell
10/21/2004WO2004046160A3 Amino-lna, thio-lna and alpha-l-oxy-ln
10/21/2004WO2004043428A3 Buccal, polar and non-polar spray or capsule containing drugs for treating pain
10/21/2004WO2004043405A3 Polysaccharide vaccine for staphylococcal infections
10/21/2004WO2004043369A3 Sulfonamides
10/21/2004WO2004041250A3 Nanoparticulate fibrate formulations
10/21/2004WO2004039315A3 Method for treating wounds to promote healing
10/21/2004WO2004037201A3 Topical skin care composition
10/21/2004WO2004037200A3 Reticulocyte depletion signatures
10/21/2004WO2004037186A3 Prophylactic treatment methods
10/21/2004WO2004037181A3 Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
10/21/2004WO2004032844A3 Compositions and methods for treating pain
10/21/2004WO2004028468A3 Methods and compositions for treatment of neurological disorder
10/21/2004WO2004028451A8 β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA
10/21/2004WO2004024728A3 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
10/21/2004WO2004009556A9 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
10/21/2004WO2004006867A3 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents
10/21/2004WO2003103614A3 Compositions for the treatment of edematous-firbrosclerotic panniculopathy
10/21/2004WO2003097163A3 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
10/21/2004WO2003096980A3 Bicyclic modulators of androgen receptor function
10/21/2004WO2003080803A3 Methods of using farnesoid x receptor (fxr) agonists
10/21/2004WO2003072757A9 Nucleotide mimics and their prodrugs
10/21/2004WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
10/21/2004WO2003049599A8 Methods and compositions for the diagnosis of asthma
10/21/2004WO2003045228A3 Methods for treating autoimmune disorders, and reagents related thereto
10/21/2004WO2003043631A3 Method for identification of tumor targeting enzymes
10/21/2004WO2003027266A3 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
10/21/2004WO2003024392A3 Compositions and methods for the diagnosis and treatment of tumor
10/21/2004WO2003004025A8 High purity amlodipine benzenesulfonate and a process for its preparation
10/21/2004WO2002094210A3 Cosmetic agents
10/21/2004WO1995018619A9 Bicyclic fibrinogen antagonists
10/21/2004US20040210950 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS)
10/21/2004US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders
10/21/2004US20040210079 selective monoamine oxidase B inhibitors; neurodegenerative diseases; Alzheimer's Disease
10/21/2004US20040210061 Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
10/21/2004US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles
10/21/2004US20040209963 dispersing in an aqueous phase a solution of an active substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing mixture and separating dispersion from gaseous solvent; dispersed particles are in micro or nano size range
10/21/2004US20040209961 Treatment of intestinal conditions with N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
10/21/2004US20040209960 particularly tetrodotoxin-resistant sodium channel modulators and/or activity-dependent sodium channel modulators, including but are not limited to compounds that modulate or interact with Nav.1.8 and/or Nav1.9 channels such as Ralfinamide, Ambroxol, and Topiramate
10/21/2004US20040209958 Use of aryl nitrone compounds in methods for treating neuropathic pain
10/21/2004US20040209957 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke
10/21/2004US20040209956 S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate form II crystalline salt
10/21/2004US20040209955 preservative-free aqueous solution of sodium gamma-hydroxybutyrate, and a pH adjusting agent; pH of 6-7.5; chemically stable and resistant to microbial growth
10/21/2004US20040209954 administering an anticholinergic quaternary amine such as glycopyrrolate, mepenzolate or ipratropium.
10/21/2004US20040209952 Composition containing chalcone
10/21/2004US20040209950 3-(substituted phenoxy)-2-methyl-2-(haloalkoxybenzoylamino)propionitrile derivatives; especially for treating helminths, in warm-blooded productive livestock and domestic animals.
10/21/2004US20040209944 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection
10/21/2004US20040209942 treating cancer and apoptosis-associated disorders using cell cycle checkpoint activation modulators; also screening for the modulators
10/21/2004US20040209941 administering inhibitor of the renin-angiotensin system such as quinapril; for AIDS patients under retroviral therapy
10/21/2004US20040209940 potent antibacterial activity against various bacteria including drug-resistant strains
10/21/2004US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/21/2004US20040209937 Treatment of excessive osteolysis with indolinone compounds
10/21/2004US20040209935 Pyrazole-derived kinase inhibitors and uses thereof
10/21/2004US20040209934 Protein phosphate inhibitors
10/21/2004US20040209933 containing a p-[4-(1H-[1,2,3]triazolyl)butyl]phenoxymethyl group, e.g., 1-(4-{4-[2-(2-Benzo[1,3]dioxol-5-yl-vinyl)-oxazol-4-ylmethoxy]-phenyl}-butyl)-1H-[1,2,3]triazole or salt; anticancer agents
10/21/2004US20040209932 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
10/21/2004US20040209930 Synergistic methods and compositions for treating cancer
10/21/2004US20040209929 Fused heteroaryl carboxylic acids as PPAR agonists
10/21/2004US20040209927 administering a aminostilbazole, e.g., E)-4-[2-{2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl}ethenyl]pyridine 1-oxide as a Vpr function regulator, useful in the treatment of HIV or AIDS,
10/21/2004US20040209922 Pyridine matrix metalloproteinase inhibitors
10/21/2004US20040209920 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
10/21/2004US20040209919 2-[(2-pyridyl)methylsulfinyl]benzimidazole derivative stabilized with an inorganic salt of magnesium, calcium, potassium, or sodium; gastric acid secretion inhibitors
10/21/2004US20040209916 treating chronic obstructive pulmonary disease by administering a quarternary ammonium compound, and an Adenosine A2a or D2-Dopamine Receptor Agonist, PDE or norepinephrine reuptake Inhibitor, corticosteroid, or 4-hydroxy-7-[phenylethoxypropylsulphonylethylaminoethyl]benzothiazol-2(3H)-one.
10/21/2004US20040209915 substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity
10/21/2004US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
10/21/2004US20040209911 Mixture containing rapamycin; absorption efficiency
10/21/2004US20040209909 in a carrier effective to permit sustained release at a therapeutically effective rate over an administration period of at least 8 hours
10/21/2004US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments
10/21/2004US20040209907 administering anagrelide, anagrelide in base form, or a salt of anagrelide so that first pass liver metabolism is avoided.
10/21/2004US20040209906 Composition comprising ketanserin AND AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS
10/21/2004US20040209902 Aminoquinoline compounds
10/21/2004US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors.
10/21/2004US20040209900 administering pentoxifylline to reduce abnormal accumulation of fat in either the cervico-thoracic area or in the abdominal region; reducing facial wrinkles
10/21/2004US20040209899 A2B adenosine receptor antagonists
10/21/2004US20040209898 preparation of the EPCRS form by heating the Risperidone in an organic solvent(s) followed by subsequent cooling and isolation to get desired polymorph
10/21/2004US20040209897 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
10/21/2004US20040209895 inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases
10/21/2004US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine
10/21/2004US20040209893 treatment of a condition mediated by a tachykinin including substance P and other neurokinins by administering N-benzyl-2-phenylpiperazine-1-carboxamides, e.g., 2-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic Acid (3,5-bistrifuoromethyl-benzyl)-methyl-amide Hydrochloride .
10/21/2004US20040209891 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
10/21/2004US20040209890 Polyhydroxyalkylpyrazine derivatives, their preparation and medicaments comprising them
10/21/2004US20040209889 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
10/21/2004US20040209888 Methods of treating dry eye disorders
10/21/2004US20040209887 Pyrrolo[1,2-B]pyridazine compounds and their uses
1 ... 4917 4918 4919 4920 4921 4922 4923 4924 4925 4926 4927 4928 4929 4930 4931 4932 4933 4934 4935 4936 4937 ... 7860